Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2

Journal of Immunotherapy

Volumn 21, Issue 1, 1998, Pages 75-83

  Sen, Goutam ^a   Chakraborty, Mala ^a   Foon, Kenneth A ^a   Reisfeld, Ralph A ^b   Bhattacharya Chatterjee, Malaya ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anti idiotype antibodies; Rabbit; Rodent; Tumor immunity; Vaccination

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; GANGLIOSIDE GD2; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXICITY; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MELANOMA; MICE; MICE, INBRED BALB C; RABBITS;

EID: 0031963116     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199801000-00010     Document Type: Article

References (36)

1. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995;145:147-66.
2. Lloyd KO. Tumor antigens known to be immunogenic in man. In: Bystryn JC, Ferrone S, Livingston P, eds. Specific immunotherapy of cancer with vaccines. New York: The New York Academy of Sciences, 1993:50-8.
3. Livingston PO, Ritter G, Oettgen HF, Old LJ. Immunization of melanoma patients with purified gangliosides. In: Oettgen HF, ed. Gangliosides and cancer. New York: VCH Publishers, 1989:293-300.
4. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985;35:607-12.
5. Vadhan-Raj S, Cordon-Cardo C, Carswell EA, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6:1636-48.
6. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8.
7. Cheung NKV, Cheung IY, Canete A, et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994;54:2228-33.
8. Handgretinger R, Baader P, Dopfer R, et al. A Phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a. Cancer Immunol Immunother 1992;35:199-204.
9. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-7.
10. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 1993;53:566-73.
11. Hamilton WB, Helling F, Livingston PO. Ganglioside expression on sarcoma and small cell lung carcinoma compared to tumors of neuroectodermal origin. Proc Am Assoc Cancer Res 1993;34:491.
12. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104.
13. Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18. Cancer Res 1989;49:2857-61.
14. Cheung NKV, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a Phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40.
15. Handgretinger R, Anderson K, Lang P, et al. A Phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31 A:261-7.
16. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody Chi4.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992;3:19-24.
17. Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with anti-ganglioside GD2 antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15:29-37.
18. Albertini MR, Gan J, Jaeger P, et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother 1996;19:278-95.
19. Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 1984;81:5767-71.
20. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 1986;102:688-96.
21. Cazenave PA. Idiotypic-anti-idiotypic regulation of antibody synthesis in rabbits. Proc Natl Acad Sci USA 1977;74:5122-5.
22. Bona C, Herber-Katz E, Paul E. Idiotype-antiidiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J Exp Med 1981;153:951-67.
23. Livingston PO, Adluri S, Helling F, et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994;12:1275-80.
24. Kensil CR, Patel U, Lennick M, Merciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria monila cortex. J Immunol 1991;146:431-7.
25. + cytotoxic T-lymphocyte responses. J Immunol 1992;148:2357-62.
26. Bhattacharya-Chatterjee M, Pride MW, Seon BK, Kohler H. Idiotype vaccines against human T-cell acute lymphoblastic leukemia (TALL). I. Generation and characterizations of biologically active monoclonal anti-idiotypes. J Immunol 1987;5:562-73.
27. Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, Seon BK, Kohler H. Idiotype vaccines against T-cell leukemia. II. Generation and characterization of monoclonal idiotype cascade (Abl, Ab2 and Ab3). J Immunol 1988;141:1398-403.
28. Chakraborty M, Foon KA, Kohler H, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimics the carcinoembryonic antigen. J Immunother 1995;18:95-103.
29. Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 1991;88:186-92.
30. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer Res 1989;49:191-6.
31. Anderson DR, McCoobery RE. Idiotype network response to murine immunoglobulin G3 anti-carbohydrate antibodies. J Immunother 1992;11:267-73.
32. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993:151:3390-8.
33. Cheung NKV, Cante A, Cheung IY, Ye J, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 1993;54:499-505.
34. Yamamoto S, Yamamoto T, Saxton RE, Hoon DSB, Irie RF. Antiidiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990;82:1757-60.
35. Hastings A, Morrison SL, Kanda S, Saxton RE, Irie RF. Production and characterization of a murine human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Res 1992;52:1681-6.
36. McCaffery M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996;2:679-86.